ArriVent BioPharma (AVBP) announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 study in first-line EGFR exon20 insertion mutant non-small cell lung cancer, NSCLC, is projected to be in early 2026. The primary endpoint will assess progression free survival, PFS, by blinded independent central review, BICR, per Response Evaluation Criteria in Solid Tumors, RECIST, 1.1. In the first quarter of 2025, the study completed enrollment across global sites.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma, Inc.: Promising Developments and Strategic Advancements Drive Buy Rating
- ArriVent Biopharma resumed with a Buy at Goldman Sachs
- ArriVent BioPharma Announces $75 Million Public Offering
- ArriVent Biopharma 2.5M share Spot Secondary priced at $19.50
- ArriVent Biopharma announces $75M common stock, warrants offering